

MINIREVIEW

# Adenosine Monophosphate–Activated Kinase and Its Key Role in Catabolism: Structure, Regulation, Biological Activity, and Pharmacological Activation

Sukriti Krishan, Des R. Richardson, and Sumit Sahni

*Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales, Australia*

Received September 11, 2014; accepted November 21, 2014

## ABSTRACT

Adenosine monophosphate–activated protein kinase (AMPK) is a cellular energy sensor, which once activated, plays a role in several processes within the cell to restore energy homeostasis. The protein enhances catabolic pathways, such as  $\beta$ -oxidation and autophagy, to generate ATP, and inhibits anabolic processes that require energy, including fatty acid, cholesterol, and protein synthesis. Due to its key role in the regulation of critical cellular pathways, deregulation of AMPK is associated with the pathology of many diseases, including cancer, Wolff-Parkinson-White syndrome, neurodegenerative disorders, diabetes, and metabolic

syndrome. In fact, AMPK is a target of some pharmacological agents implemented in the treatment of diabetes (metformin and thiazolidinediones) as well as other naturally derived products, such as berberine, which is used in traditional medicine. Due to its critical role in the cell and the pathology of several disorders, research into developing AMPK as a therapeutic target is becoming a burgeoning and exciting field of pharmacological research. A profound understanding of the regulation and activity of AMPK would enhance its development as a promising therapeutic target.

## General Introduction

Adenosine monophosphate–activated protein kinase (AMPK) belongs to a family of highly conserved, heterotrimeric, serine-threonine kinases, with orthologs present in all eukaryotes (Kahn et al., 2005). AMPK is an energy sensor that is activated during cellular stress (Hardie, 2007). During low energy conditions, it increases catabolic processes to generate ATP and inhibits anabolic processes that require ATP (Hardie, 2007). The protein is activated through phosphorylation of Thr172 in the  $\alpha$ -subunit by three main kinases under different stimuli, namely, liver kinase B1 (LKB1) (Woods et al., 2003), calmodulin-mediated kinase kinase  $\beta$  (CaMKK $\beta$ ) (Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005; Anderson et al., 2008), and transforming growth factor- $\beta$  activated kinase 1 (TAK1) (Momcilovic et al., 2006). Along with phosphorylation, AMPK also requires allosteric activation through AMP binding to the  $\gamma$ -subunit (Suter

et al., 2006). Once activated, AMPK stimulates  $\beta$ -oxidation (Hardie, 1989), glucose uptake (Kurth-Kraczek et al., 1999), and autophagy (Egan et al., 2011; Kim et al., 2011), while inhibiting cellular proliferation and the synthesis of fatty acids (Hardie and Pan, 2002), cholesterol (Habegger et al., 2012), and protein (Gwinn et al., 2008). Hence, AMPK is a critical enzyme involved in the regulation and integration of catabolic and anabolic pathways.

Due to its central role in regulating multiple processes within the cell, AMPK deregulation is associated with several pathologic conditions, including diabetes and other metabolic diseases (Hardie, 2011), cancer (Faubert et al., 2013), neurodegeneration (Lopez-Lopez et al., 2007; Lim et al., 2012), and cardiac hypertrophy (Gollob et al., 2001a). The key role of AMPK in these conditions makes it a promising therapeutic target, and this is discussed in the final section of the review.

## Structure and Regulation of AMPK

**Structure of AMPK.** AMPK belongs to a family of serine-threonine protein kinase complexes that exist as a heterotrimer

D.R.R. is the recipient of a National Health and Medical Research Council Senior Principal Research Fellowship and Project Grants.

The authors declare no conflict of interest.

D.R.R. and S.S. contributed equally to this work.

dx.doi.org/10.1124/mol.114.095810.

**ABBREVIATIONS:** AD, Alzheimer's disease; AICAR, 5-aminoimidazole-4-carboxamide riboside; AMPK, adenosine monophosphate–activated protein kinase; CaMK, calmodulin-dependent kinase; CBM, carbohydrate binding motif; CBS, cystathionine- $\beta$ -synthase; GAP, GTPase-activating proteins; HD, Huntington's disease; HMGCoA, hydroxymethylglutaryl CoA; HMGCR, hydroxymethylglutaryl-CoA reductase; mTOR, mammalian target of rapamycin; PD, Parkinson's disease; Rheb, Ras homolog enriched in brain; S6K, S6 kinase; SGLT, sodium dependent glucose cotransporter; STRAD, STE20-related pseudokinase; TZDs, thiazolidinediones; WPW, Wolff-Parkinson-White syndrome; ZMP, AICAR 5'-monophosphate.

composed of a catalytic subunit (AMPK $\alpha$ ) and two regulatory subunits (AMPK $\beta$  and AMPK $\gamma$ ) (Fig. 1, A and B) (Hardie, 2007; Carling et al., 2008). The AMPK $\alpha$  and AMPK $\beta$  subunits have two isoforms each ( $\alpha 1$ ,  $\alpha 2$  and  $\beta 1$ ,  $\beta 2$ ), and the AMPK $\gamma$  subunit exists as three different isoforms ( $\gamma 1$ ,  $\gamma 2$ , and  $\gamma 3$ ) (Hardie, 2011) (Table 1). These isoforms of the AMPK subunits interact with each other to form 1 of 12 possible heterotrimers in different tissues (Hardie, 2007).


AMPK $\alpha$  is the catalytic subunit of the protein (Hardie, 2007). Complexes containing the  $\alpha 1$  isoform were shown to be predominantly expressed in the liver and adipose tissue, whereas the AMPK $\alpha 2$  complexes were localized to the brain, heart, and skeletal muscle (Steinberg and Kemp, 2009; O'Neill, 2013). Furthermore, the AMPK $\alpha 1$  isoform has been shown to localize intracellularly in the cytosol, whereas the AMPK $\alpha 2$  isoform is primarily found in the nucleus (Salt et al., 1998). The N-terminal of the protein harbors the kinase domain that extends from residues 1–280, comprising Thr172 in the activation loop, which is phosphorylated for kinase activity (Carling et al., 1994; Halford et al., 2003; Suter et al., 2006) (Fig. 1B). The C-terminal of the protein has the autoinhibitory regulatory sequence of ~70 residues next to the kinase domain (Chen et al., 2009) and a C-terminal  $\beta/\gamma$ -subunit interacting domain ( $\alpha$ -CTD) extending from residues 395–550 (Fig. 1B) (Jiang and Carlson, 1997; Xiao et al., 2007). Furthermore, the final 20 residues at the C-terminal end were shown to be conserved across diverse species (Brenman and Temple, 2007), and it was recently identified as the nuclear export sequence (Kazgan et al., 2010) (Fig. 1B).

To date, little is known about the nuclear and cytoplasmic pools of AMPK and how its intracellular distribution is controlled. However, it has been shown that post-translational modifications of the AMPK $\beta 1$  subunit affect enzyme activity

and cellular distribution of the trimeric protein (Warden et al., 2001; Oakhill et al., 2010, 2011). AMPK $\beta$  exists in two isoforms. The first isoform is AMPK $\beta 1$ , which is a 270-amino acid (30-kDa) protein, whereas AMPK $\beta 2$  is a protein consisting of 272 amino acids (34 kDa). Both isoforms are 71% identical and differ mostly at the N-terminal region (Thornton et al., 1998). Additionally, there have been studies showing that the carbohydrate-binding module (CBM) of the  $\beta 2$  subunit binds more tightly to oligosaccharides when compared with the  $\beta 1$  subunit (Koay et al., 2010). One of the main reasons for this was shown to be a single threonine insertion at position 101 in AMPK $\beta 2$  after Trp99 (Koay et al., 2010). The latter residue has been shown to be essential for oligosaccharide binding and glycogen association in vitro (Polekhina et al., 2005; McBride et al., 2009), and insertion of Thr101 in the CBM region of the  $\beta 1$  subunit resulted in an increased affinity for oligosaccharides (Koay et al., 2010).

Similar to AMPK $\alpha$ , the expression of AMPK $\beta$  varies in different tissues (Thornton et al., 1998; Chen et al., 1999; Winder, 2001). AMPK $\beta 1$  is predominantly expressed in the liver, pancreas, kidney, brown fat, and brain, while AMPK $\beta 2$  is expressed in cardiac and skeletal muscle (Thornton et al., 1998; Chen et al., 1999; Winder, 2001). Furthermore, studies have demonstrated that each AMPK $\beta$  isoform has distinct roles in different tissues (Dzamko et al., 2010; Dasgupta et al., 2012). AMPK $\beta 1$  was shown to have a role primarily in the liver, with AMPK $\beta 1$ -null mice demonstrating reduced fasting gluconeogenesis and enhanced hepatic insulin sensitivity (Dzamko et al., 2010). In addition, decreased AMPK $\beta 1$  activity led to defective proliferation and differentiation, unregulated apoptosis, and neuronal loss in the brains of these mice (Dasgupta and Milbrandt, 2009).

On the other hand, AMPK $\beta 2$ -containing complexes play a crucial role in regulating glucose, glycogen, and lipid metabolism



**Fig. 1.** Structure of AMPK. (A) Crystal structure of AMPK. The  $\alpha$ -subunit is indicated in yellow, orange, and cyan, the  $\beta$ -subunit is in green, with the CBM in bright green, and the  $\gamma$ -subunit is in pink. For this structure, an AMPK complex, which was phosphorylated on Thr172, was crystallized in the presence of AMP and the kinase inhibitor stauroporine. Additionally, AMPK activator 991, shown in magenta, is bound in a pocket generated at the interface between the CBM and kinase domain. Only AMP binding at CBS site 3 is shown (marked as AMP-3). Reprinted with permission from Macmillan Publishers Ltd: [Nature] (Xiao et al., 2013), (<http://creativecommons.org/licenses/by/3.0/legalcode>). (B) The  $\alpha$ -subunit is a 550 amino acid long catalytic subunit and is composed of the kinase domain,  $\alpha$ -linker region, the C-terminal  $\beta/\gamma$ -subunit interacting domain ( $\alpha$ -CTD), and a nuclear export signal. The  $\alpha$ -linker region contains the autoinhibitory sequence and  $\alpha$ -hook domain. The kinase domain is phosphorylated at Thr172 in the activation loop. The  $\beta$ -subunit is 270 amino acids long and has a CBM and the C-terminal domain of the  $\beta$ -subunit,  $\beta$ -CTD. The N-terminal contains a more variable sequence, including the N-myristoylation site. The  $\gamma$ -subunit contains four tandem repeats of the CBS AMP-binding pockets (i.e., CBS 1–4).

TABLE 1  
AMPK subunits.

The gene encoding the subunits, their chromosomal location, molecular weight, and transcript size.

Subunit	Gene	Location	MW	Transcript	
			<i>Da</i>		
AMPK $\alpha$ 1	<i>PRKAA1</i>	5p12	64,009	1929 bp	(Strausberg et al., 2002; Krishan et al., 2014)
AMPK $\alpha$ 2	<i>PRKAA2</i>	1p31	62,320	1703 bp	(Strausberg et al., 2002)
AMPK $\beta$ 1	<i>PRKAB1</i>	12q24.1-q24.3	30,382	813 bp	(Gao et al., 1996; Mitchelhill et al., 1997)
AMPK $\beta$ 2	<i>PRKAB2</i>	1q21.1	30,302	819 bp	(Gao et al., 1996)
AMPK $\gamma$ 1	<i>PRKAG1</i>	12q12-q14	37,579	996 bp	(Gao et al., 1996)
AMPK $\gamma$ 2	<i>PRKAG2</i>	7q36.1	63,066	1962 bp	(Ota et al., 2004)
AMPK $\gamma$ 3	<i>PRKAG3</i>	2q35	54,258	1599 bp	(Gao et al., 1996)

MW, molecular weight; bp, base pair

in skeletal muscle during metabolic stress (Steinberg et al., 2010; Dasgupta et al., 2012). Studies using AMPK $\beta$ 2-null mice demonstrated that these animals showed hyperglycemia, glucose intolerance, and insulin resistance and were unable to maintain muscle ATP levels during exercise (Steinberg et al., 2010; Dasgupta et al., 2012). The AMPK $\beta$  subunit contains the CBM region (residues 75–157) (Jiang and Carlson, 1996, 1997; McBride et al., 2009) and the C-terminal domain of the  $\beta$ -subunit near the C-terminal of the subunit at approximately residues 186–270 (Iseli et al., 2005) (Fig. 1B).

The CBM region in the  $\beta$ -subunit plays a role in the binding of glycogen to AMPK and allows the protein to detect changes in glycogen levels in the cell (McBride et al., 2009). Additionally, this region is also involved in the interaction of the  $\alpha$ -subunit kinase domain with the regulatory fragment, which consists of the C-terminal domains of the  $\alpha$ - and  $\beta$ -subunits and all domains of the  $\gamma$ -subunit (Momcilovic et al., 2008; Xiao et al., 2011, 2013). More recently, the CBM region was also shown to be involved in protecting AMPK from cellular phosphatases (Xiao et al., 2013), such as human protein phosphatase-2 $\alpha$  (PP2C $\alpha$ ) (Davies et al., 1995). In fact, the CBM region binds to the *N*-lobe of the kinase domain and is also connected to the regulatory fragment (Xiao et al., 2013). It has been suggested that an AMPK activator, namely, compound 991, promotes the interaction between the kinase and CBM region to protect active AMPK against dephosphorylation (Xiao et al., 2013). Furthermore, replacing ADP/AMP with ATP resulted in the displacement of the  $\alpha$ -hook (discussed in detail below; also referred to as regulatory subunit-interacting motif; residues  $\alpha$ 1<sub>359–365</sub> and  $\alpha$ 2<sub>365–371</sub>) (Chen et al., 2013; Xiao et al., 2013; Xin et al., 2013). Xiao et al. speculated that this alteration leads to the dissociation of the kinase domain and CBM from the regulatory fragment (Xiao et al., 2013). In this form, the kinase is no longer allosterically activated and is susceptible to dephosphorylation and thus inactivation (Xiao et al., 2011, 2013). The second domain, C-terminal domain of the  $\beta$ -subunit, was shown to bind with both the  $\alpha$ - and  $\gamma$ -subunits in mammalian cells and acts as an anchoring region (Iseli et al., 2005) (Fig. 1B). Furthermore, the N-terminal has a more variable sequence that regulates *N*-myristoylation, which is important for membrane targeting and binding (Oakhill et al., 2010) (Fig. 1B). This study also showed that this post-translational modification of the protein is crucial for AMPK activation via AMP binding, as loss of the myristoyl group abolished AMP activation and reduced the extent of  $\alpha$ -Thr172 phosphorylation (Oakhill et al., 2010).

The AMPK $\gamma$  subunit acts as an allosteric activator of the AMPK complex (Hardie, 2011). It contains four tandem repeats of a structural module called the cystathionine- $\beta$ -synthase

(CBS) motif (Fig. 1B) (Bateman, 1997), which is involved in AMP/ADP binding, a critical step in AMPK activation (Hardie, 2011). A recent study revealed that three of the four AMP-binding sites (i.e., CBS) can be occupied by other nucleoside phosphates, such as ATP, ADP, or AMP (Xiao et al., 2011). One of these sites (CBS site 4) was believed to have AMP permanently bound to it (Kemp et al., 2007), but more recent studies have shown that the AMP can be exchanged for an ATP at this site (Zhu et al., 2011; Chen et al., 2012). The two sites, namely, CBS sites 1 and 3, which are sometimes referred to as exchangeable sites, bind AMP or ATP, and this allows the protein to respond to alterations in AMP/ATP levels (Xiao et al., 2007, 2011; Oakhill et al., 2012). However, unlike AMP binding, ATP binding does not result in a conformational change of the protein structure (Carling et al., 1989; Xiao et al., 2011). AMP/ADP binds to the weaker of the two exchangeable sites (i.e., CBS site 3), which interacts with the  $\alpha$ -hook region (Xiao et al., 2011, 2013). The Glu368( $\alpha$ 2-hook) residue has been shown to form salt bridges with Lys170( $\gamma$ ) and possibly Arg70( $\gamma$ ). These latter sites are suggested to mediate the initial signaling distinguishing nucleotide binding (Xiao et al., 2011, 2013). This interaction leads to restricted flexibility of the  $\alpha$ -linker region (residues 300–370), promoting the interaction of the kinase domain with the regulatory fragment (Xiao et al., 2011; Xin et al., 2013). This conformation protects the activation loop from dephosphorylation by phosphatases (Xiao et al., 2011, 2013). Alternatively, ATP binding leads to a steric clash of the regulatory fragment with the  $\alpha$ -hook, causing the  $\alpha$ -hook to dissociate, and this increases the flexibility of the linker that promotes dissociation of the kinase domain (Xiao et al., 2011, 2013). In this form, the activation loop is no longer protected by packing against the regulatory fragment and is accessible to attack by phosphatases (Xiao et al., 2011). Thus, the shift between AMP/ADP or ATP binding determines the change in conformation between dephosphorylation sensitive and insensitive states (Xiao et al., 2011).

**Regulation of AMPK Activity.** The AMPK protein is activated by two crucial mechanisms. First, Thr172 in the activation loop of the  $\alpha$ -subunit is phosphorylated by one of the three main upstream kinases: LKB1 (Woods et al., 2003), CaMKK $\beta$  (Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005; Anderson et al., 2008), and TAK1 (Momcilovic et al., 2006) (Fig. 2). Second, AMP binding to the  $\gamma$ -subunit of AMPK leads to allosteric activation of AMPK (Carling et al., 2008) (Fig. 2).

LKB1 phosphorylates the Thr172 residue on the AMPK $\alpha$  subunit (Hurley et al., 2005) during low cellular energy conditions and was found to be the key upstream kinase (Woods

et al., 2003) (Fig. 2). Alternatively, activation by CaMKK $\beta$  occurs as a response to increased cytosolic calcium levels (Hawley et al., 2005) (Fig. 2). Furthermore, along with activating AMPK, AMP binding also protects phosphorylated Thr172 from the activity of phosphatases (Davies et al., 1995) (Fig. 2). The mechanisms through which TAK1 activates AMPK are still uncharacterized (Momcilovic et al., 2006).


**Activation of AMPK by LKB1.** The key upstream kinase of AMPK, namely, LKB1, acts as a tumor suppressor in several cancers (Gan and Li, 2014) and is also mutated (loss of function) in Peutz-Jeghers syndrome (Hemminki et al., 1998), with most of the subjects carrying just one allele of this mutation. LKB1 has several phosphorylation sites that are either phosphorylated by upstream kinases (Collins et al., 2000), such as ataxia telangiectasia mutated kinase (Sapkota et al., 2002b), cAMP-dependent kinase (Collins et al., 2000; Sapkota et al., 2001), p90RSK (Sapkota et al., 2001), and protein kinase C $\zeta$  (Song et al., 2008), or by autophosphorylation (Sapkota et al., 2002a; Xie et al., 2009).

In addition to phosphorylation, activation of LKB1 requires STE20-related pseudokinase (STRAD) and mouse protein-25 (MO25) binding to LKB1 to form the LKB1/STRAD/MO25 complex (Boudeau et al., 2003) (Fig. 2). Formation of this complex stabilizes LKB1, activates its kinase activity (Boudeau et al., 2003), and allows the protein to translocate from the nucleus to the cytoplasm (Baas et al., 2003, 2004). This translocation might have an effect on phosphorylation of nuclear AMPK, but further studies are required to confirm this. When in the cytoplasm, the LKB1/STRAD/MO25 complex phosphorylates proteins of the AMPK family (Hawley et al., 2003) (Fig. 2). It has been proposed that under physiologic conditions, the net phosphorylation at Thr172 is determined by the balance between the rates of phosphorylation and dephosphorylation, and under basal conditions, the rate of dephosphorylation is high, resulting in low net phosphorylation (Hawley et al., 2003). However, under high AMP

conditions, AMP binding to the AMPK $\gamma$  subunit causes a conformational change in the protein structure and inhibits the dephosphorylation of Thr172 on the AMPK $\alpha$  subunit, allowing it to remain phosphorylated (Davies et al., 1995; Sanders et al., 2007; Suter et al., 2006; Xiao et al., 2013). Furthermore, it has been shown that AMP binding to AMPK enhanced the LKB1-mediated phosphorylation at Thr172 (Gowans et al., 2013). More recent studies have reported that activation of AMPK by LKB1 may take place on the lysosomal surface, suggesting a role of the late endosome/lysosome in controlling metabolic programs (Zhang et al., 2014a).

**Activation of AMPK by CaMKK $\beta$ .** CaMKK $\beta$  is another key upstream kinase of AMPK and belongs to the Ca<sup>2+</sup>/calmodulin-dependent protein kinase (CaMK) family (Berridge, 2001) (Fig. 2). The two most well characterized substrates of CaMKK $\beta$  are CaMKI and CaMKIV, but more recently, AMPK was also shown to be a target (Hawley et al., 2005). Unlike LKB1, CaMKK $\beta$  does not phosphorylate AMPK in response to low ATP levels but as a reaction to increased cytosolic calcium (Ca<sup>2+</sup>) levels (Green et al., 2011) (Fig. 2). Generally, calcium is known to regulate many processes within the cell by forming a complex with calmodulin (Chin and Means, 2000; Berridge, 2001). Studies have shown that even though CaMKK $\beta$  possesses autonomous activity, it requires Ca<sup>2+</sup>/calmodulin binding to phosphorylate AMPK at Thr172 (Hurley et al., 2005).

**Activation of AMPK by TAK1.** TAK1 is one of the most recently discovered activators of AMPK and is a member of the mitogen-activated protein kinase kinase family (Herrero-Martin et al., 2009) (Fig. 2). Its activity is regulated by various cytokines, including interleukin-1 (Landstrom, 2010), transforming growth factor- $\beta$  (Yamaguchi et al., 1995), and toll-like receptors (Landstrom, 2010), CD40, and B cell receptors (Landstrom, 2010). Once activated, TAK1 then stimulates further downstream kinases, including the p38 mitogen-activated protein kinase (Shim et al., 2005), c-Jun



**Fig. 2.** Regulation of AMPK activity. AMPK is phosphorylated by three kinases: LKB1, CaMKK $\beta$ , and TAK1. LKB1 forms a complex with STRAD and MO25, which then allows it to translocate from the nucleus to the cytoplasm. Once in the cytoplasm, LKB1 can phosphorylate AMPK at Thr172. CaMKK $\beta$  phosphorylates AMPK as a response to increased cytosolic Ca<sup>2+</sup> levels. TAK1 is activated by interleukin-1, transforming growth factor- $\beta$ , toll-like receptor, CD40, and B cell receptors. Furthermore, AMP binding to the  $\gamma$ -subunit of AMPK prevents the dephosphorylation of Thr172 in the  $\alpha$ -subunit.

N-terminal kinase (JNK) (Shim et al., 2005), and I $\kappa$ B kinase complex (IKK) (Ninomiya-Tsuji et al., 1999; Shim et al., 2005). Interestingly, TAK1 was also shown to directly phosphorylate Thr172 on the AMPK $\alpha$  subunit (Herrero-Martin et al., 2009) (Fig. 2). Furthermore, mice carrying a cardiac-specific dominant negative mutation for TAK1 showed signs of the Wolff-Parkinson-White (WPW) syndrome, which were similar to those signs associated with mutations in human AMPK $\alpha/\gamma$  (Xie et al., 2006).

Despite extensive investigation of the topic, the mechanism behind AMPK activation by TAK1 remains elusive. Some studies have suggested that TAK1 indirectly phosphorylates AMPK via activating LKB1 (Inokuchi-Shimizu et al., 2014). However, TAK1 has also been shown to directly activate AMPK (Scholz et al., 2010). Additionally, a recent study suggests AMPK acts as an activator of TAK1, and that these two proteins reciprocally regulate their activation (Kim et al., 2012b).

Once activated, AMPK regulates several different metabolic processes in cells (Hardie, 2011). In most cells, including skeletal and cardiac muscle, liver, and adipose tissue, AMPK stimulates fatty acid oxidation, mitochondrial biogenesis, glucose transporter type 4 (GLUT4) translocation, and glucose uptake, while inhibiting protein synthesis, gluconeogenesis, and fatty acid and cholesterol synthesis (Steinberg and Kemp, 2009; Srivastava et al., 2012; Ruderman et al., 2013). Insulin secretion from pancreatic  $\beta$ -cells can be inhibited by AMPK (Steinberg and Kemp, 2009), and it has been shown that AMPK can increase food intake via activating signaling in the hypothalamus (Minokoshi et al., 2004). AMPK also initiates autophagy, a catabolic process that is activated during starvation or stress (Egan et al., 2011; Kim et al., 2011). Overall, AMPK plays a major role in regulating energy homeostasis through the modulation of cellular metabolism (Hardie, 1989; Habegger et al., 2012), protein synthesis, and cellular proliferation (Shackelford and Shaw, 2009).

## Biologic Functions of AMPK

**Regulation of Metabolism and Glucose Uptake.** AMPK plays a critical role in regulating  $\beta$ -oxidation, fatty acid, and cholesterol synthesis (Hardie, 2007, 2011) (Fig. 3). Catabolism of fatty acids via  $\beta$ -oxidation results in the generation of acetyl CoA, which then enters the citric acid cycle to generate ATP (Eaton et al., 1996). On the other hand, both fatty acid and cholesterol synthesis are anabolic processes, and hence require ATP (Wakil et al., 1983; Horton et al., 2002). Fatty acid synthesis is a multistep energy consuming process that generates fatty acids from acetyl CoA and malonyl CoA (Wakil et al., 1983) (Fig. 3). Similarly, cholesterol is synthesized *in vivo* from acetyl CoA to generate hydroxymethylglutaryl CoA (HMGCoA) (Horton et al., 2002). The HMGCoA is then converted into mevalonate, which is the committed step in the cholesterol synthesis pathway (Horton et al., 2002) (Fig. 3).

AMPK regulates these processes by phosphorylating and inhibiting the enzymes acetyl CoA carboxylase 1 (ACC1) (Bianchi et al., 1990; Hardie and Pan, 2002) and hydroxymethylglutaryl CoA reductase (HMGCR) (Habegger et al., 2012) (Fig. 3). The enzymes ACC1/ACC2 and HMGCR are rate-limiting steps in the synthesis of fatty acids and cholesterol, respectively (Bianchi et al., 1990; Hardie and Pan, 2002; Habegger et al., 2012). Importantly, ACC1/ACC2 is required for the carboxylation of


acetyl CoA to malonyl CoA (Wakil et al., 1958; Thampy, 1989; Bianchi et al., 1990). Malonyl CoA subsequently inhibits carnitine palmitoyltransferase 1 (Bremer, 1963), an enzyme essential for enabling activated long chain fatty acids to enter the mitochondrion for metabolism via the  $\beta$ -oxidation pathway (Fig. 3). This process eventually results in increased ATP synthesis (Bremer, 1963; Fritz and Yue, 1963). Hence, inhibition of ACC1 by AMPK results in increased activity of carnitine palmitoyltransferase 1, leading to enhanced  $\beta$ -oxidation and ATP synthesis. Furthermore, inhibition of acetyl CoA carboxylation to malonyl CoA by AMPK interrupts fatty acid synthesis (Wakil et al., 1983) (Fig. 3). Similarly, upon phosphorylation, HMGCR is inactivated and leads to reduced cholesterol synthesis (Habegger et al., 2012) by preventing the reduction of HMGCoA to mevalonate (Horton et al., 2002) (Fig. 3).

AMPK has also been shown to suppress fatty acid synthesis by inhibiting the activity of the sterol regulatory element-binding protein-1 (SREBP1) (Li et al., 2011) (Fig. 3). SREBP1 is a transcription factor that upregulates the expression of fatty acid synthase and ACC1 (Hardie, 1989). Both of these latter enzymes are crucial for the *de novo* synthesis of fatty acids, and by inhibiting SREBP1, AMPK inhibits the expression of fatty acid synthase and ACC1 (Hardie, 1989) (Fig. 3). These effects result in decreased *de novo* fatty acid synthesis that requires ATP hydrolysis (Foretz et al., 1999).

Apart from regulating energy expenditure, studies have shown that AMPK translocates GLUT4 from intracellular storage vesicles to the plasma membrane, resulting in increased glucose uptake into the cell (Fig. 3) (Kurth-Kraczek et al., 1999). Translocation and fusion of the GLUT4 vesicles is regulated by the Rab family of G proteins when bound to GTP (active form) (Steinberg and Kemp, 2009). Rabs are inactivated by Rab GTPase-activating proteins (Rab GAPs), such as Akt substrate 160 (also known as TBC1D4) and TBC1D1 (Sano et al., 2003; Cartee and Wojtaszewski, 2007; Roach et al., 2007; Steinberg and Kemp, 2009). Phosphorylation of Akt substrate 160 promotes its association with the 14-3-3 scaffolding protein (Kramer et al., 2006; Chen et al., 2008; Pehmoller et al., 2009; Steinberg and Kemp, 2009), resulting in inhibition of its Rab GAP activity (Fig. 3). Chen et al. observed regulatory interactions among different phosphorylation sites of TBC1D1. For example, phosphorylation at Ser235 prevented subsequent phosphorylation at Ser237 (Chen et al., 2008). Phosphorylated TBC1D1 was also shown to bind the 14-3-3 scaffolding protein, resulting in its inactivation (Chen et al., 2008). Moreover, these authors also showed that AMPK activators, such as 5-aminoimidazole-4-carboxamide riboside (AICAR) and phenformin, phosphorylated TBC1D1 (Chen et al., 2008). In contrast, TBC1D4 was phosphorylated in response to insulin but not AMPK activators (Chen et al., 2008). Hence, inactivation of Rab GTPases by AMPK prevents the hydrolysis of Rab GTP (Steinberg and Kemp, 2009), which then enhances GLUT4 translocation to the plasma membrane and increases glucose uptake into the cell (Pehmoller et al., 2009).

Collectively, AMPK plays an important role in energy homeostasis via increasing catabolic pathways, including  $\beta$ -oxidation, and inhibiting anabolic processes, such as fatty acid and cholesterol synthesis.

**AMPK Regulates Signaling via the Mammalian Target of Rapamycin.** AMPK plays a role in controlling protein synthesis and cellular growth by inhibiting the mammalian



**Fig. 3.** Regulation of energy homeostasis by AMPK. AMPK phosphorylates ACC1 and inactivates it. ACC1 is required to convert acetyl CoA to malonyl CoA for fatty acid (FA) synthesis. Malonyl CoA inhibits carnitine palmitoyltransferase 1, a protein that enables the entry of FAs into the mitochondria for  $\beta$ -oxidation. Phosphorylation of ACC1 by activated AMPK prevents acetyl CoA from being converted to malonyl CoA, and thus prevents the inhibition of  $\beta$ -oxidation. Furthermore, inhibition of malonyl CoA synthesis also prevents FA synthesis. AMPK also suppresses ACC1 levels by inhibiting SREBP1, a transcription factor involved in ACC1 transcription. Similarly, inhibition of HMGCR via phosphorylation by AMPK prevents cholesterol synthesis by interrupting the conversion of HMGCoA to mevalonate. In addition to this, AMPK also regulates glucose uptake by increasing GLUT4 translocation to the membrane.

target of rapamycin (mTOR) pathway (Gwinn et al., 2008) (Fig. 4). The mTOR complex 1 (mTORC1) plays a critical role as a nutrient/energy/redox sensor and controls protein synthesis (Kim et al., 2002). The complex, mTORC1, is composed of mTOR1 and the regulatory-associated protein of mTOR (raptor), which phosphorylates eukaryotic translation initiation factor 4E-binding protein (4EBP1) and ribosomal S6 kinase (S6K) (Fig. 4) (Holz et al., 2005; Wullschlegler et al., 2006).


AMPK has been shown to suppress mTORC1 by a dual mechanism, namely 1) by inhibiting PI3K/AKT signaling (Shaw, 2009; Menon et al., 2014), and 2) by directly inhibiting raptor (Gwinn et al., 2008) (Fig. 4). AKT inhibits the tuberous sclerosis 1/2 complex by phosphorylating tuberous sclerosis 2 (TSC2) serine residues. A recent study by Menon et al. showed that the AKT-mediated phosphorylation of TSC2 does not affect its GAP activity (Menon et al., 2014). Rather, this phosphorylation of TSC2 by AKT was shown to stimulate the dissociation of TSC complex from Ras homolog-enriched in brain (Rheb) at the lysosomal surface and the activation of Rheb (Menon et al., 2014). In contrast, when AMPK is activated, it phosphorylates TSC2 at distinct serine sites (e.g., Ser1387) than those targeted by other kinases (Shaw, 2009). This AMPK-mediated phosphorylation of TSC2 results in the activation of the tuberous sclerosis 1/2 complex, which leads to inactivation of Rheb (Inoki et al., 2003; Shaw, 2009). This inactivation of Rheb results in inhibition of mTORC1 signaling (Inoki et al., 2003). Furthermore, AMPK also directly inhibits mTORC1 by phosphorylating raptor (Gwinn et al., 2008). This phosphorylation allows 14-3-3-binding to raptor, which reduces mTORC1 activity (Gwinn et al., 2008) (Fig. 4).

Inhibition of mTORC1 by AMPK leads to suppression of 4EBP1 and S6K phosphorylation (Wullschlegler et al., 2006; Holz et al., 2005). When phosphorylated, 4EBP1 is unable to bind and inhibit the translational initiation factor eIF4E, resulting in an accumulation of free eIF4E and increased protein translation

(Haghighat et al., 1995; Gingras et al., 1999) (Fig. 4). Furthermore, S6K upregulates the translation of proteins, such as hypoxia-inducible factor 1 $\alpha$ , MYC, and cyclin D1 (Guertin and Sabatini, 2007), which are involved in cell cycle progression and cell growth. Hence, suppression of mTORC1 by AMPK results in decreased protein synthesis and cellular proliferation (Fig. 4) (Shackelford and Shaw, 2009). The suppressive effect of AMPK on cell proliferation could lead to its development as an important therapeutic target in proliferative disorders, such as cancer and atherosclerosis (Motoshima et al., 2006).

**AMPK as an Initiator of Autophagy.** AMPK is an important initiator of autophagy, a catabolic process that is activated during starvation or stress (Choi, 2012). Autophagy regulates the digestion of cellular macromolecules and even whole organelles by engulfing the organelles and proteins in a double membrane vesicle (autophagosomes), which fuse with the lysosomes to hydrolyze its contents (Choi, 2012; Sahni et al., 2014). Autophagy acts as a mechanism of avoiding cell death, but under some conditions, can lead to autophagic cell death (Choi, 2012).

Once AMPK is activated, it phosphorylates an initiator of autophagy, Unc 51-like kinase (ULK1), at certain sites, namely, Ser317 and Ser777 (Kim et al., 2011) (Fig. 5). Phosphorylation of ULK1 at these sites is important for initiation of autophagy (Kim et al., 2011). Another study has shown that AMPK also phosphorylates ULK1 at Ser467, Ser555, Thr574, and Ser637 (Egan et al., 2011). Additionally, ULK1 is also phosphorylated by mTORC1 at Ser757, which has an inhibitory effect on the phosphorylation of ULK1 at Ser317 and Ser777, resulting in suppression of the autophagic pathway (Kim et al., 2011) (Fig. 5). As discussed earlier, when active, AMPK suppresses mTORC1 activity, which leads to decreased phosphorylation of ULK1 at Ser757 (Kim et al., 2011). The removal of the inhibitory phosphorylation at Ser757 allows ULK1 to be phosphorylated at Ser317 and Ser777 by AMPK, which results in the activation of




**Fig. 4.** Regulation of mTORC1 by AMPK. AMPK inhibits mTOR signaling via a dual mechanism. First, AMPK inhibits raptor and prevents the formation of mTORC1. Second, AMPK also interferes with PI3K/AKT signaling by phosphorylating and activating the TSC1/TSC2 dimer, which inhibits Rheb. Rheb is an activator of mTORC1. Hence, activation of the TSC1/TSC2 dimer by AMPK results in suppression of Rheb, which is then unable to activate mTORC1. Suppression of mTORC1 leads to inhibition of ribosomal S6K and eukaryotic translation initiation factor 4EBP1 phosphorylation. Nonphosphorylated 4EBP1 can bind to translation factor eIF4E and prevent protein synthesis. This leads to decreased protein translation, which then results in decreased cell proliferation.

autophagy (Kim et al., 2011) (Fig. 5). Thus, AMPK initiates autophagy directly by activating ULK1 and also by removing the inhibitory effect of mTORC1 on ULK1 (Fig. 5). Together, the suppression of mTORC1 and activation of ULK1 by AMPK leads to inhibition of protein synthesis (an ATP-consuming process) and activation of autophagy in the cell, leading to prolonged survival.

### AMPK in Pathologic Conditions

**Diabetes and Metabolic Diseases.** As AMPK is a potent regulator of cellular metabolism, it plays a crucial role in type 2 diabetes and several other metabolic diseases (Hardie, 2011). Previous studies have indicated that an elevation of plasma fatty acid levels could lead to impaired insulin-mediated glucose uptake (Frayn et al., 1993), which requires the translocation of GLUT4 to the plasma membrane (Cushman et al.,



**Fig. 5.** Regulation of autophagy by AMPK. AMPK regulates autophagy through a dual mechanism. First, AMPK phosphorylates ULK1 at Ser317/777, which results in initiation of autophagy. Second, AMPK also indirectly enhances ULK1 phosphorylation at these sites by suppression of mTORC1. mTORC1 phosphorylates ULK1 at Ser757, but this phosphorylation has an inhibitory effect on the phosphorylation of Ser317/777. Hence, suppression of mTORC1 removes the inhibitory phosphorylation on ULK1 and allows it to be phosphorylated at Ser317/777.

1998). Considering that AMPK is involved in regulating both fatty acid metabolism (Hardie, 1989) and GLUT4 translocation to the membrane (Kurth-Kraczek et al., 1999), reduced activity of AMPK activity would be expected to inhibit fatty acid oxidation and decrease glucose uptake into the cell. Furthermore, AMPK activators have been shown to improve insulin resistance and glucose uptake in rodent models of the metabolic syndrome (Song et al., 2002; Habegger et al., 2012). These activators also prevented the development of diabetes, lipid deposition, and degranulation of pancreatic islet  $\beta$  cells (Yu et al., 2004). Furthermore, AMPK is expressed in adipose tissue and is involved in metabolic regulation in these cells (Wang et al., 2014). Hence, due to the correlation between excess adiposity and metabolic diseases (Abate et al., 1995; Premanath et al., 2014), this suggests another possible pathway through which AMPK plays a role in these disorders. These studies illustrate a crucial role of AMPK in metabolic diseases and diabetes, and signify its importance as a molecular target for novel therapeutics.

**Wolff-Parkinson-White Syndrome.** WPW syndrome is a genetic disorder caused by mutations in the *PRKAG2* gene, which codes for the AMPK $\gamma$ 2 subunit (Gollob et al., 2001a,b; Gollob and Roberts, 2002). As discussed earlier, the  $\gamma$ -subunit is essential for the allosteric activation of the protein (Bateman, 1997; Hardie, 2007). Previous studies have demonstrated that *PRKAG2* gene mutations, such as His142Arg, Arg302Gln, His383Arg, Thr400Asn, Tyr487His, Asn488Ile, Gln506Lys, Arg531Gly, Ser548Pro, and InsLeu351, occur in the CBS region of the gene and affect the AMP-binding ability of the subunit (Gollob and Roberts, 2002). However, this notion has been challenged by a recent study in Chinese patients that has discovered a new missense mutation, namely, Gly100Ser

(G100S), in the *PRKAG2* gene, but unlike the other mutations, this one was not in the CBS region (Zhang et al., 2013). Over-expression of this mutated protein resulted in a thicker heart wall, increased glycogen storage and decreased AMPK enzymatic activity (Zhang et al., 2014b). Cardiomyocytes from patients with the WPW syndrome exhibit a variable phenotype consisting of cardiac hypertrophy, pre-excitation, and conduction abnormalities, which are probably caused by the derangement of AMPK's function (Light, 2006). *PRKAG2*-induced cardiac syndrome is believed to be a result of increased glycogen storage (Gollob, 2003). Studies have shown an accumulation of glycogen-like substances in the myocardium, which leads to increased thickness of the myocardium, i.e., cardiac hypertrophy (Arad et al., 2003). Apart from causing cardiac hypertrophy, increased glycogen storage in cardiomyocytes interferes with electrical conductance (Gollob, 2003). This problem leads to the development of a less efficient accessory pathway (Gollob, 2003), which is another electrical conduction system that connects the atrium to the ventricle (Ho, 2008). Furthermore, studies have suggested that the increased glucose uptake in these cells leads to an increase in cytosolic glucose-6-phosphate and consequent activation of glycogen synthesis (Luptak et al., 2007). However, the effect of *PRAKG2* mutation on cardiac growth was shown to be independent of glycogen storage (Kim et al., 2014). In contrast, the electrical defects in these cardiomyocytes seem to be secondary consequences of the high glycogen content (Kim et al., 2014).

Initially, WPW was believed to be due to a loss of function mutation (Sidhu et al., 2005). However, studies have shown that the increased glycogen storage was due to a gain of function mutation in the *PRKAG2* gene (Banerjee et al., 2007; Gollob et al., 2001b). Recent evidence from transgenic mouse studies suggest that some *PRKAG2* mutations, such as N488I, lead to increased AMPK activity and accumulation of glycogen in myocytes, contributing to cardiac hypertrophy (Arad et al., 2003). Another mutation located at R302Q within the AMPK $\gamma$ 2 subunit was also identified and shown to amplify glycogen storage in cardiac muscle (Gollob et al., 2001b; Gollob, 2003). However, there are conflicting data that show that mice expressing the  $\gamma$ 2 R302Q variant have reduced AMPK activity when measured with the SAMS peptide (Sidhu et al., 2005), a well established AMPK substrate widely used for determination of AMPK activity (Davies et al., 1989). A similar  $\gamma$ 2 mutation, T400N, when expressed in transgenic mice, resulted in a biphasic effect of the  $\gamma$ 2 subunit on cardiac muscle AMPK activity, with increased activity in samples from young mice, but reduced activity later in life (Banerjee et al., 2007). These conflicting findings suggest that the lower AMPK activity observed in older mice might be due to secondary effects of the mutation acquired later in life (Banerjee et al., 2007). These studies suggest deregulation of AMPK activity caused by *PRKAG2* mutations leads to the development of WPW, but the mechanisms by which these mutations in the *PRKAG2* gene cause WPW syndrome are not clearly defined.

Furthermore, more recent data have shown that knockdown of cardiac sodium-dependent glucose cotransporter (SGLT) in mice with the *PRKAG2* Thr400Asn mutation (TGT400N) attenuates the phenotype consisting of cardiomyopathy (Ramratnam et al., 2014). Transgenic mice with cardiac SGLT1 over-expression replicate phenotypic features of the cardiomyopathy, suggesting a role for SGLT1 in the pathophysiology of the *PRKAG2* mutation (Ramratnam et al., 2014).

**Neurodegenerative Diseases.** Several studies have shown AMPK over-activation in neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) (Chou et al., 2005; Lopez-Lopez et al., 2007; Lim et al., 2012). Additionally, neurodegenerative diseases (e.g., PD) are also associated with mitochondrial dysfunction (Panov et al., 2002; Ruan et al., 2004; Milakovic and Johnson, 2005). Mitochondrial dysfunction can lead to high lactate levels in PD brains (Harms et al., 1997), which can result in activation of AMPK (Chen et al., 2010). A recent study demonstrated that exposure of neuronal cells to lactate caused an AMPK-dependent accumulation of  $\alpha$ -synuclein in the cytoplasm (Jiang et al., 2013), a protein associated with PD development.

In HD, it has been demonstrated that the AMPK $\alpha$ 1 subunit abnormally translocates to the nucleus in the striatal neurons expressing the mutant *huntingtin* gene (Ju et al., 2011). This resulted in the suppression of Bcl2 (an antiapoptotic protein) expression, leading to neurotoxicity (Ju et al., 2011). Furthermore, this study also showed that the pharmacological agent CGS21680, which ameliorates HD symptoms, acts in part by preventing AMPK $\alpha$ 1 translocation to the nucleus (Ju et al., 2011). In the case of AD, the role of AMPK in the progression of this disease is still not clear. In human patients, it was observed that AMPK is abnormally activated and translocated from the nucleus to the cytoplasm in AD tangles (Vingtdeux et al., 2011). It was demonstrated that AMPK activation, either directly or indirectly, inhibits tau phosphorylation in rat cortical neurons (Greco et al., 2009). Conversely, other studies have demonstrated that AMPK phosphorylates tau at multiple sites and disrupts the binding of tau to microtubules (Thornton et al., 2011; Vingtdeux et al., 2011). From these findings, it is evident that AMPK is activated during Alzheimer's disease. However, it is not clear if it is the primary cause or a cellular response to repair the damage, for example, through the activation of autophagy.

**Controversial Role of AMPK in Cancer.** Current evidence indicates that AMPK has properties of both a tumor suppressor and a tumor promoter (Bonini and Gantner, 2013). The role of AMPK in cancer is discussed in detail in a recent review by Jones and colleagues (Faubert et al., 2014). It has been suggested that AMPK inhibits tumor growth through its regulation of metabolic pathways (Shackelford and Shaw, 2009). As cancer cells generally have high energy expenditure due to their more rapid metabolism, it would seem that AMPK, as a master regulator of energy homeostasis, would play a key role in tumor progression (Faubert et al., 2013). Additionally, LKB1, the key upstream kinase of AMPK, has been shown to inhibit cancer proliferation as well as metastasis, possibly through AMPK activation (Gan and Li, 2014).


Metastasis is an important step in the progression of cancer. It involves the detachment of tumor cells from their primary site and their dissemination to distant sites via blood vessels and the lymphatic system (Geiger and Peeper, 2009). Cell polarity can also be observed in migrating cells and is responsible for directional migration (Marcus and Zhou, 2010). Loss of polarity may be responsible for the epithelial to mesenchymal transition and subsequent tumor invasion, which plays a key role in metastasis (Thiery, 2003).

It has been noted that AMPK regulates mammalian cell motility, and its loss causes directional migration defects (Nakano et al., 2010), suggesting a potential role for AMPK

in energy-dependent regulation of cell motility (Fig. 6). Interestingly, AMPK phosphorylates the microtubule plus end protein CLIP-170 to regulate cell polarity via microtubule dynamics (Fig. 6) (Zheng and Cantley, 2007). CLIP-170 directly binds newly polymerized distal ends of growing microtubules and rapidly dissociates from the older microtubule lattice (Dragestein et al., 2008). Microtubules induce cell polarity by transporting protein complexes to the new end of the cell (Sawin and Nurse, 1998). Inhibition of AMPK leads to an accumulation of nonphosphorylated CLIP-170 and disturbed cell polarity (Nakano et al., 2010), suggesting a role of AMPK in maintaining polarity.

A recent study has shown that activation of AMPK reduces metastasis and invasion by downregulating the levels of integrin  $\beta 1$  (Park et al., 2012), which is known to participate in cell migration (Lee et al., 2010). Integrins mediate adhesion to the extracellular matrix, but also participate in the regulation of cytoskeletal organization of the cell (Banno and Ginsberg, 2008), making it important for cell migration and invasion. Hence, reducing integrin  $\beta 1$  levels would lead to reduced cell migration and invasion. In addition to regulating cell polarity, studies have shown that suppression of metastasis by AMPK occurs through its ability to inhibit S6K (Taliaferro-Smith et al., 2009). Activation of AMPK resulted in the inhibition of the mTORC1 pathway (Gwinn et al., 2008), resulting in suppressed expression of proteins required for tumor growth and metastasis, including HIF-1 $\alpha$ , MYC, and cyclin D1 (Guertin and Sabatini, 2007).

Interestingly, there have also been studies showing that AMPK elevates tumor growth and metastasis. One investigation suggested that AMPK activation during energy stress prolongs cell survival by redox regulation (Jeon et al., 2012). Under these conditions, NADPH generation through the pentose phosphate pathway was down-regulated, but AMPK was able to induce alternative metabolic routes to maintain NADPH levels and inhibit cell death (Jeon et al., 2012). Inhibition of ACC1 by AMPK decreases NADPH consumption in fatty acid synthesis and increases NADPH generation by means of fatty acid oxidation (Jeon et al., 2012). Other investigations have suggested that the prosurvival role of AMPK can be attributed to the induction of autophagy and



**Fig. 6.** AMPK regulates cell polarity and directional migration. AMPK phosphorylates the microtubule plus end protein CLIP-170, which is involved in the binding of newly polymerized distal ends of growing microtubules and rapidly dissociates from the older microtubule lattice. This results in directional migration of cells.

the maintenance of proliferative quiescence (Degenhardt et al., 2006). It has been suggested that AMPK activation, and therefore autophagy, can serve as a protective mechanism conferring resistance to growth factor deprivation therapies (Chhipa et al., 2011). Overall, these studies suggest that AMPK promotes tumor growth by inhibiting cell death and prolonging cell survival through autophagy under stressful conditions (Degenhardt et al., 2006; Chhipa et al., 2011; Jeon et al., 2012).

From the investigations described above, it is evident that AMPK plays a primary role in regulating tumor growth and metastasis. While there is some controversy regarding the antitumor and protumor effects of AMPK, the majority of studies have demonstrated that AMPK plays a crucial role in inhibiting tumor growth and metastasis.

### Therapeutic Targeting of the AMPK Signaling Pathway

Due to the diverse roles of AMPK in the cell as well as its regulation in several pathologic conditions, AMPK acts as a promising therapeutic target for the treatment of a number of pathologic conditions (Hardie, 2013; Russo et al., 2013; Jeong et al., 2014). There are several known physiologic, pharmacological, natural, and hormone activators of AMPK, with some of these already being used clinically (Corton et al., 1995; Zhou et al., 2001; Lee et al., 2006). Currently, pharmaceutical agents, such as metformin and thiazolidinediones (TZDs), are used for the treatment of type 2 diabetes via their ability to activate the AMPK pathway (Owen et al., 2000). These agents are discussed in detail below.

**Metformin.** Metformin (Fig. 7A) is used as a treatment of type 2 diabetes (Duncan and Seaton, 1962) as well as polycystic ovarian syndrome (Diamanti-Kandarakis et al., 2010) and metabolic syndrome (Bianchi et al., 2007). The efficacy of metformin in these metabolic disorders is attributed to its ability to reduce hepatic gluconeogenesis and improve insulin sensitivity (Viollet et al., 2012). Metformin activates AMPK indirectly by inhibiting complex I of the mitochondrial respiratory chain, which promotes a switch from aerobic to anaerobic glycolysis to increase the cellular AMP/ATP ratio (Owen et al., 2000; Zhou et al., 2001; Hawley et al., 2010). Interestingly, recent findings by Fullerton et al. show that phosphorylation of ACC1 by AMPK is required for metformin's effects on lipid metabolism and insulin sensitivity (Fullerton et al., 2013). In addition to its antidiabetic effects, studies have also shown that metformin possesses antitumor properties, including reduced cell growth, induction of apoptosis, and reduced migration and invasion in a variety of human cancer cell lines (Papanas et al., 2010; Rozengurt et al., 2010; Liu et al., 2011; Viollet et al., 2012).

Several *in vitro* and *in vivo* studies have shown that one of the potential pathways via which metformin mediates its antitumor effects is through AMPK activation and reduced mTOR activity (Zakikhani et al., 2008; Ben Sahra et al., 2010; Brown et al., 2010; Tosca et al., 2010). However, metformin also acts through AMPK-independent mechanisms (Foretz et al., 2010; Rattan et al., 2011; Janjetovic et al., 2011a,b; Miller et al., 2013). Studies have shown that LKB1 is a crucial protein required for the antitumor effects of metformin, as cells lacking LKB1 failed to exhibit reduced tumor growth when treated with this agent (Huang et al., 2008; Legro et al., 2008; Rattan et al., 2011).

Currently, numerous phase II and III clinical trials are underway to investigate the potential of treatment with metformin in a variety of tumor types, including breast cancer (Martin-Castillo et al., 2010; Goodwin et al., 2011; Hadad et al., 2011), endometrial cancer, colorectal cancer, and prostate cancer. However, some of these studies are in the recruitment stage and have yet to determine the potential of metformin as an adjuvant to current cancer therapeutics.


**Thiazolidinediones.** TZDs (e.g., rosiglitazone) (Fig. 7B) are another class of drugs used in the treatment of diabetes, which primarily target the peroxisome proliferator-activated receptor- $\gamma$  to improve insulin sensitivity (LeBrasseur et al., 2006). The effects of TZDs are partly mediated through AMPK activation (LeBrasseur et al., 2006). These drugs activate AMPK in a similar way to metformin by inhibiting complex I of the mitochondrial respiratory chain, increasing the AMP/ATP ratio (Brunmair et al., 2004; Hawley et al., 2010). Additionally, TZDs also increase AMPK activation through proliferator-activated receptor- $\gamma$  to stimulate adiponectin secretion from adipose tissue (LeBrasseur et al., 2006). Adiponectin was shown to increase AMPK phosphorylation and regulate glucose levels and stimulate fatty acid oxidation in skeletal muscle (Yoon et al., 2006). Hence, TZDs are effective drugs to treat diabetes through their ability to activate AMPK, which subsequently regulates glucose levels in cells and improves insulin sensitivity.

**5-Aminoimidazole-4-Carboxamide Riboside.** The compound AICAR (Fig. 7C) is a well known activator of AMPK (Sullivan et al., 1994; Corton et al., 1995). In fact, it was the first compound to be identified as an activator of AMPK (Sullivan et al., 1994). Structurally, AICAR is similar to AMP, and upon intracellular metabolism, it is converted to AICAR 5'-monophosphate (ZMP), an analog of AMP, by adenosine kinase (Corton et al., 1995). Activation of AMPK by ZMP is similar to that by AMP, where ZMP binds to the CBS domains on the  $\gamma$ -subunit of AMPK and leads to allosteric activation of the

complex (Corton et al., 1995). Additionally, AICAR treatment either prevented and/or reversed some aspects of metabolic syndrome in animal models, including improved glucose tolerance, better systemic glucose disposal (Song et al., 2002), and reduced hepatic glucose output, as well as plasma triglyceride and free fatty acid levels (Bergeron et al., 2001). However, AICAR does have some disadvantages that makes it unlikely to be used as a therapeutic agent, such as low bioavailability and a short half-life (Coughlan et al., 2014). Due to its ability to mimic AMP, it can interfere with several other pathways in the cell that require AMP (Longnus et al., 2003), making AICAR an unpromising lead agent for drug development.

Similar to AICAR, the drugs pemetrexed and sorafenib also increase AMPK activity through inhibition of aminoimidazole-carboxamide ribonucleotide formyl-transferase (Racanelli et al., 2009; Bareford et al., 2011). Inhibition of aminoimidazole-carboxamide ribonucleotide formyl-transferase results in increased ZMP and activation of AMPK (Bareford et al., 2011). These agents have demonstrated antitumor effects through the regulation of AMPK and subsequently autophagy (Bareford et al., 2011). Currently, these drugs are in phase I clinical trials, and it has been suggested that combination treatment with pemetrexed and sorafenib represent a future therapeutic option for the treatment of solid tumors (Bareford et al., 2011).

**Berberine.** Berberine (Fig. 7D) is a clinically important pharmacological agent derived from the *Berberis* plant species that has exhibited AMPK activation properties (Imanshahidi and Hosseinzadeh, 2008; Tillhon et al., 2012). It is used in traditional Chinese and Korean medicine to treat bacterial and fungal infections as well as type 2 diabetes (Tillhon et al., 2012). Berberine treatment using several rodent models resulted in improved glucose tolerance (Lee et al., 2006), reduced body weight (Lee et al., 2006), increased expression of both the insulin receptor and low-density lipoprotein receptor (Kong et al., 2004), lower total and low-density lipoprotein cholesterol levels, and



**Fig. 7.** Activators of AMPK. Line drawings of the structures of some of the pharmacological and natural compounds that activate AMPK. (A) Metformin. (B) Rosiglitazone (thiazolidinediones). (C) AICAR. (D) Berberine. (E) Acetyl salicylate. (F) Resveratrol.

reduced triglyceride levels (Kong et al., 2004). Studies have shown that berberine is able to lower blood glucose, triglyceride, and cholesterol levels to a similar extent as metformin (Yin et al., 2008). Collectively, these results suggested that berberine activates the AMPK pathway (Kong et al., 2004; Lee et al., 2006). Similarly to metformin, berberine was shown to act upon AMPK through inhibiting complex I of the mitochondrial respiratory chain (Turner et al., 2008; Hawley et al., 2010).

More recent studies have also demonstrated that the antitumor and antimetastatic effects of berberine are also mediated through the activation of the AMPK pathway (Kim et al., 2012a; Park et al., 2012). Another investigation showed that berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of extracellular signal-regulated kinase activity and cyclooxygenase-2 protein expression (Kim et al., 2012a). The extracellular signal-regulated kinase/cyclooxygenase-2 pathway is involved in the regulation cell proliferation, angiogenesis, and metastasis in many cancers (Muller-Decker and Furstemberger, 2007).

**Salicylates.** Salicylates are natural compounds secreted by many plants as a defense against infections, and synthetic derivatives, including acetyl salicylate (aspirin) (Fig. 7E) or diester salicylate, are used pharmaceutically (Higgs et al., 1987). Studies have shown that salicylate binds to a site in an AMPK cleft between the kinase domain of the  $\alpha$ -subunit and the CBM domain of the  $\beta$ -subunit (Hawley et al., 2012). Furthermore, it was only able to activate AMPK complexes containing the  $\beta 1$  isoform and requires  $\beta$ -Ser108 phosphorylation (Hawley et al., 2012). However, high fat-fed wild-type and AMPK $\beta 1$  knockout mice treated with salicylate showed improved glucose tolerance and reduced fasting glucose and insulin levels, suggesting AMPK-independent activity (Hawley et al., 2012). Hence, even though salicylates seem promising as an AMPK-mediated antidiabetic treatment, further research is required to determine the role of AMPK in these outcomes.

**Resveratrol.** Resveratrol (Fig. 7F) is a polyphenol found in red wine that has been shown to stimulate AMPK activity in many different cell lines (Dasgupta and Milbrandt, 2007; Park et al., 2007; Um et al., 2010). The mechanism by which resveratrol activates AMPK is thought to be attributed to an increase in AMP levels due to inhibition of the mitochondrial F<sub>1</sub> ATPase (Gledhill et al., 2007; Hawley et al., 2010). Resveratrol treatment stimulates glucose uptake (Park et al., 2007) and mitochondrial biogenesis (Baur et al., 2006) in muscle cells and reduces liver lipid accumulation (Zang et al., 2006). However, it is still unclear as to whether these effects are mediated through AMPK activation (Ruderman et al., 2010).

## Conclusions

AMPK is an important protein involved in systemic energy homeostasis. It leads to the activation of catabolic pathways, such as  $\beta$ -oxidation and autophagy, and suppression of anabolic pathways (for example, fatty acid synthesis) to provide an alternate source of energy to the cell under stressful conditions. In conclusion, AMPK is a critical cellular regulator involved in both physiologic and pathologic conditions. Due to the role of AMPK in energy homeostasis, it is implicated in a number of disorders, such as diabetes and cardiac hypertrophy, and is a promising therapeutic target. Indeed, the design of AMPK activators for therapeutic applications represents a thriving field for future research.

## Acknowledgments

The authors thank Dr. Danuta Kalinowski, Dr. Zaklina Kovacevic, Dr. Patric Jansson, Dr. Darius Lane, Dr. Angelica Merlot, and Dr. Vera Richardson for comments to improve the manuscript prior to submission.

## Authorship Contributions

Wrote or contributed to the writing of the manuscript: Krishan, Richardson, Sahni.

## References

- Abate N, Garg A, Peshock RM, Stray-Gundersen J, and Grundy SM (1995) Relationships of generalized and regional adiposity to insulin sensitivity in men. *J Clin Invest* **96**:88–98.
- Anderson KA, Ribar TJ, Lin F, Noeldner PK, Green MF, Muehlbauer MJ, Witters LA, Kemp BE, and Means AR (2008) Hypothalamic CaMKK2 contributes to the regulation of energy balance. *Cell Metab* **7**:377–388.
- Arad M, Moskowitz IP, Patel VV, Ahmad F, Perez-Atayde AR, Sawyer DB, Walter M, Li GH, Burgon PG, and Maguire CT et al. (2003) Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. *Circulation* **107**:2850–2856.
- Baas AF, Boudeau J, Sapkota GP, Smit L, Medema R, Morrice NA, Alessi DR, and Clevers HC (2003) Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. *EMBO J* **22**:3062–3072.
- Baas AF, Kuipers J, van der Wel NN, Batlle E, Koerten HK, Peters PJ, and Clevers HC (2004) Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. *Cell* **116**:457–466.
- Banerjee SK, Ramani R, Saba S, Rager J, Tian R, Mathier MA, and Ahmad F (2007) A PRKAG2 mutation causes biphasic changes in myocardial AMPK activity and does not protect against ischemia. *Biochem Biophys Res Commun* **360**:381–387.
- Banno A and Ginsberg MH (2008) Integrin activation. *Biochem Soc Trans* **36**:229–234.
- Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, and Burow ME et al. (2011) Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. *Cancer Res* **71**:4955–4967.
- Bateman A (1997) The structure of a domain common to archaeobacteria and the homocystinuria disease protein. *Trends Biochem Sci* **22**:12–13.
- Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, and Lewis K et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* **444**:337–342.
- Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, and Bertolotto C et al. (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. *Cancer Res* **70**:2465–2475.
- Bergeron R, Previs SF, Cline GW, Perret P, Russell RR, 3rd, Young LH, and Shulman GI (2001) Effect of 5-aminoimidazole-4-carboxamide-1- $\beta$ -D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. *Diabetes* **50**:1076–1082.
- Berridge MJ (2001) The versatility and complexity of calcium signalling. *Novartis Found Symp* **239**:52–64, discussion 64–67, 150–159.
- Bianchi A, Evans JL, Iverson AJ, Nordlund A-C, Watts TD, and Witters LA (1990) Identification of an isozymic form of acetyl-CoA carboxylase. *J Biol Chem* **265**:1502–1509.
- Bianchi C, Penno G, Romero F, Del Prato S, and Miccoli R (2007) Treating the metabolic syndrome. *Expert Rev Cardiovasc Ther* **5**:491–506.
- Bonini MG and Gantner BN (2013) The multifaceted activities of AMPK in tumor progression—why the “one size fits all” definition does not fit at all? *IUBMB Life* **65**:889–896.
- Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M, Prescott AR, Clevers HC, and Alessi DR (2003) MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. *EMBO J* **22**:5102–5114.
- Bremer J (1963) Carnitine in intermediary metabolism: the biosynthesis of palmitylcarnitine by cell subfractions. *J Biol Chem* **238**:2774–2779.
- Brennan JE and Temple BR (2007) Opinion: alternative views of AMP-activated protein kinase. *Cell Biochem Biophys* **47**:321–331.
- Brown KA, Hunger NI, Docanto M, and Simpson ER (2010) Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. *Breast Cancer Res Treat* **123**:591–596.
- Brunnair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, and Waldhäusl W et al. (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? *Diabetes* **53**:1052–1059.
- Carling D, Aguan K, Woods A, Verhoeven AJ, Beri RK, Brennan CH, Sidebottom C, Davison MD, and Scott J (1994) Mammalian AMP-activated protein kinase is homologous to yeast and plant protein kinases involved in the regulation of carbon metabolism. *J Biol Chem* **269**:11442–11448.
- Carling D, Clarke PR, Zammit VA, and Hardie DG (1989) Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. *Eur J Biochem* **186**:129–136.
- Carling D, Sanders MJ, and Woods A (2008) The regulation of AMP-activated protein kinase by upstream kinases. *Int J Obes (Lond)* **32** (Suppl 4):S55–S59.
- Cartee GD and Wojtaszewski JF (2007) Role of Akt substrate of 160 kDa in insulin-stimulated and contraction-stimulated glucose transport. *Appl Physiol Nutr Metab* **32**:557–566.

- Chen JL, Merl D, Peterson CW, Wu J, Liu PY, Yin H, Muoio DM, Ayer DE, West M, and Chi JT (2010) Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. *PLoS Genet* **6**:e1001093.
- Chen L, Jiao Z-H, Zheng L-S, Zhang Y-Y, Xie S-T, Wang Z-X, and Wu J-W (2009) Structural insight into the autoinhibition mechanism of AMP-activated protein kinase. *Nature* **459**:1146–1149.
- Chen L, Wang J, Zhang YY, Yan SF, Neumann D, Schlattner U, Wang ZX, and Wu JW (2012) AMP-activated protein kinase undergoes nucleotide-dependent conformational changes. *Nat Struct Mol Biol* **19**:716–718.
- Chen L, Xin FJ, Wang J, Hu J, Zhang YY, Wan S, Cao LS, Lu C, Li P, and Yan SF et al. (2013) Conserved regulatory elements in AMPK. *Nature* **498**:E8–E10.
- Chen S, Murphy J, Toth R, Campbell DG, Morrice NA, and Mackintosh C (2008) Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. *Biochem J* **409**:449–459.
- Chen Z, Heierhorst J, Mann RJ, Mitchellhill KI, Michell BJ, Witters LA, Lynch GS, Kemp BE, and Stapleton D (1999) Expression of the AMP-activated protein kinase beta1 and beta2 subunits in skeletal muscle. *FEBS Lett* **460**:343–348.
- Chhipa RR, Wu Y, and Ip C (2011) AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia. *Cell Signal* **23**:1466–1472.
- Chin D and Means AR (2000) Calmodulin: a prototypical calcium sensor. *Trends Cell Biol* **10**:322–328.
- Choi KS (2012) Autophagy and cancer. *Exp Mol Med* **44**:109–120.
- Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH, Wu YC, Sun CN, Chien CL, and Lin YS et al. (2005) CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. *J Neurochem* **93**:310–320.
- Collins SP, Reoma JL, Gamm DM, and Uhler MD (2000) LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. *Biochem J* **345**:673–680.
- Corton JM, Gillespie JG, Hawley SA, and Hardie DG (1995) 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? *Eur J Biochem* **229**:558–565.
- Coughlan KA, Valentine RJ, Ruderman NB, and Saha AK (2014) AMPK activation: a therapeutic target for type 2 diabetes? *Diabetes Metab Syndr Obes* **7**:241–253.
- Cushman SW, Goodyear LJ, Pilch PF, Ralston E, Galbo H, Ploug T, Kristiansen S, and Klip A (1998) Molecular mechanisms involved in GLUT4 translocation in muscle during insulin and contraction stimulation. *Adv Exp Med Biol* **441**:63–71.
- Dasgupta B, Ju JS, Sasaki Y, Liu X, Jung SR, Higashida K, Lindquist D, and Milbrandt J (2012) The AMPK  $\beta$ 2 subunit is required for energy homeostasis during metabolic stress. *Mol Cell Biol* **32**:2837–2848.
- Dasgupta B and Milbrandt J (2007) Resveratrol stimulates AMP kinase activity in neurons. *Proc Natl Acad Sci USA* **104**:7217–7222.
- Dasgupta B and Milbrandt J (2009) AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. *Dev Cell* **16**:256–270.
- Davies SP, Carling D, and Hardie DG (1989) Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay. *Eur J Biochem* **186**:123–128.
- Davies SP, Helps NR, Cohen PT, and Hardie DG (1995) 5'-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. *FEBS Lett* **377**:421–425.
- Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, and Fan Y et al. (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. *Cancer Cell* **10**:51–64.
- Diamanti-Kandarakis E, Economou F, Palimeri S, and Christakou C (2010) Metformin in polycystic ovary syndrome. *Ann N Y Acad Sci* **1205**:192–198.
- Dragestein KA, van Cappellen WA, van Haren J, Tsidibid GD, Akhmanova A, Knoch TA, Grosfeld F, and Galjart N (2008) Dynamic behavior of GFP-CLIP-170 reveals fast protein turnover on microtubule plus ends. *J Cell Biol* **180**:729–737.
- Duncan LJ and Seaton DA (1962) The treatment of diabetes mellitus with metformin. *Br J Clin Pract* **16**:129–132.
- Dzambo N, van Denderen BJ, Hevener AL, Jørgensen SB, Honeyman J, Galic S, Chen ZP, Watt MJ, Campbell DJ, and Steinberg GR et al. (2010) AMPK beta1 deletion reduces appetite, preventing obesity and hepatic insulin resistance. *J Biol Chem* **285**:115–122.
- Eaton S, Bartlett K, and Pourfarzam M (1996) Mammalian mitochondrial beta-oxidation. *Biochem J* **320**:345–357.
- Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, Vasquez DS, Joshi A, Gwinn DM, and Taylor R et al. (2011) Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. *Science* **331**:456–461.
- Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, and Viollet B et al. (2013) AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. *Cell Metab* **17**:113–124.
- Faubert B, Vincent EE, Poffenberger MC, and Jones RG (2014) The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. *Cancer Lett* DOI: 10.1016/j.canlet.2014.01.018 [published ahead of print].
- Foretz M, Guichard C, Ferré P, and Foulfelle F (1999) Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. *Proc Natl Acad Sci USA* **96**:12737–12742.
- Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, and Viollet B (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. *J Clin Invest* **120**:2355–2369.
- Frayn KN, Coppack SW, Humphreys SM, Clark ML, and Evans RD (1993) Periprandial regulation of lipid metabolism in insulin-treated diabetes mellitus. *Metabolism* **42**:504–510.
- Fritz IB and Yue KT (1963) Long-chain carnitine acyltransferase and the role of acylcarnitine derivatives in the catalytic increase of fatty acid oxidation induced by carnitine. *J Lipid Res* **4**:279–288.
- Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulinilkunnit T, Chen ZP, O'Neill HM, Ford RJ, Palanivel R, and O'Brien M et al. (2013) Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. *Nat Med* **19**:1649–1654.
- Gan RY and Li HB (2014) Recent progress on liver kinase B1 (LKB1): expression, regulation, downstream signaling and cancer suppressive function. *Int J Mol Sci* **15**:16698–16718.
- Gao G, Fernandez CS, Stapleton D, Auster AS, Widmer J, Dyck JR, Kemp BE, and Witters LA (1996) Non-catalytic beta- and gamma-subunit isoforms of the 5'-AMP-activated protein kinase. *J Biol Chem* **271**:8675–8681.
- Geiger TR and Peepers DS (2009) Metastasis mechanisms. *Biochim Biophys Acta* **1796**:293–308.
- Gingras A-C, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, and Sonenberg N (1999) Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. *Genes Dev* **13**:1422–1437.
- Gledhill JR, Montgomery MG, Leslie AG, and Walker JE (2007) Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. *Proc Natl Acad Sci USA* **104**:13632–13637.
- Gollob MH (2003) Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome. *Biochem Soc Trans* **31**:228–231.
- Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Ahmad F, Lozado R, Shah G, and Fananapazir L et al. (2001a) Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. *N Engl J Med* **344**:1823–1831.
- Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, and Roberts R (2001b) Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. *Circulation* **104**:3030–3033.
- Gollob MH and Roberts R (2002) AMP-activated protein kinase and familial Wolff-Parkinson-White syndrome: new perspectives on heart development and arrhythmogenesis. *Eur Heart J* **23**:679–681.
- Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, and Mayer IA et al. (2011) Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. *Breast Cancer Res Treat* **126**:215–220.
- Gowans GJ, Hawley SA, Ross FA, and Hardie DG (2013) AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. *Cell Metab* **18**:556–566.
- Greco SJ, Sarkar S, Johnston JM, and Tezapsidis N (2009) Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. *Biochem Biophys Res Commun* **380**:98–104.
- Green MF, Anderson KA, and Means AR (2011) Characterization of the CaMKK $\beta$ -AMPK signaling complex. *Cell Signal* **23**:2005–2012.
- Guertin DA and Sabatini DM (2007) Defining the role of mTOR in cancer. *Cancer Cell* **12**:9–22.
- Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, and Shaw RJ (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Mol Cell* **30**:214–226.
- Habegger KM, Hoffman NJ, Ridenour CM, Brozinick JT, and Elmendorf JS (2012) AMPK enhances insulin-stimulated GLUT4 regulation via lowering membrane cholesterol. *Endocrinology* **153**:2130–2141.
- Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, and Pusztai L et al. (2011) Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. *Breast Cancer Res Treat* **128**:783–794.
- Haghighat A, Mader S, Pause A, and Sonenberg N (1995) Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. *EMBO J* **14**:5701–5709.
- Halford NG, Hey S, Jhurreea D, Laurie S, McKibbin RS, Paul M, and Zhang Y (2003) Metabolic signalling and carbon partitioning: role of Snf1-related (SnRK1) protein kinase. *J Exp Bot* **54**:467–475.
- Hardie DG (1989) Regulation of fatty acid synthesis via phosphorylation of acetyl-CoA carboxylase. *Prog Lipid Res* **28**:117–146.
- Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. *Nat Rev Mol Cell Biol* **8**:774–785.
- Hardie DG (2011) AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. *Biochem Soc Trans* **39**:1–13.
- Hardie DG (2013) AMPK: a target for drugs and natural products with effects on both diabetes and cancer. *Diabetes* **62**:2164–2172.
- Hardie DG and Pan DA (2002) Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. *Biochem Soc Trans* **30**:1064–1070.
- Harms L, Meierkord H, Timm G, Pfeiffer L, and Ludolph AC (1997) Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. *J Neurol Neurosurg Psychiatry* **62**:27–30.
- Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Mäkelä TP, Alessi DR, and Hardie DG (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. *J Biol* **2**:28.
- Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevzoff C, Walker KJ, Pegg MW, Zibrova D, Green KA, and Mustard KJ et al. (2012) The ancient drug salicylate directly activates AMP-activated protein kinase. *Science* **336**:918–922.
- Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG, and Hardie DG (2005) Calmodulin-dependent protein kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. *Cell Metab* **2**:9–19.
- Hawley SA, Ross FA, Chevzoff C, Green KA, Evans A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, and Evans AM et al. (2010) Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. *Cell Metab* **11**:554–565.

- Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, and Höglund P et al. (1998) A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature* **391**:184–187.
- Herrero-Martín G, Höyer-Hansen M, García-García C, Fumarola C, Farkas T, López-Rivas A, and Jäättelä M (2009) TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. *EMBO J* **28**:677–685.
- Higgs GA, Salmon JA, Henderson B, and Vane JR (1987) Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and anti-inflammatory activity. *Proc Natl Acad Sci USA* **84**:1417–1420.
- Ho SY (2008) Accessory atrioventricular pathways: getting to the origins. *Circulation* **117**:1502–1504.
- Holz MK, Ballif BA, Gygi SP, and Blenis J (2005) mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. *Cell* **123**:569–580.
- Horton JD, Goldstein JL, and Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J Clin Invest* **109**:1125–1131.
- Huang X, Wullschlegler S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S, and Alessi DR (2008) Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. *Biochem J* **412**:211–221.
- Hurley RL, Anderson KA, Franzoni JM, Kemp BE, Means AR, and Witters LA (2005) The Ca<sup>2+</sup>/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. *J Biol Chem* **280**:29060–29066.
- Imanshahidi M and Hosseinzadeh H (2008) Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. *Phytother Res* **22**:999–1012.
- Inoki K, Li Y, Xu T, and Guan KL (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. *Genes Dev* **17**:1829–1834.
- Inokuchi-Shimizu S, Park EJ, Roh YS, Yang L, Zhang B, Song J, Liang S, Pimental M, Taniguchi K, and Wu X et al. (2014) TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis. *J Clin Invest* **124**:3566–3578.
- Iseli TJ, Walter M, van Denderen BJ, Katsis F, Witters LA, Kemp BE, Michell BJ, and Stapleton D (2005) AMP-activated protein kinase beta subunit tethers alpha and gamma subunits via its C-terminal sequence (186-270). *J Biol Chem* **280**:13395–13400.
- Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N, Sumarac-Dumanovic M, Micic D, and Trajkovic V (2011a) In vitro and in vivo anti-melanoma action of metformin. *Eur J Pharmacol* **668**:373–382.
- Janjetovic K, Vucicevic L, Misirkic M, Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S, Bumbasirevic V, and Trajkovic V et al. (2011b) Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. *Eur J Pharmacol* **651**:41–50.
- Jeon SM, Chandel NS, and Hay N (2012) AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. *Nature* **485**:661–665.
- Jeong KJ, Kim GW, and Chung SH (2014) AMP-activated protein kinase: an emerging target for ginseng. *J Ginseng Res* **38**:83–88.
- Jiang P, Gan M, Ebrahim AS, Castanedes-Casey M, Dickson DW, and Yen SH (2013) Adenosine monophosphate-activated protein kinase overactivation leads to accumulation of  $\alpha$ -synuclein oligomers and decrease of neurites. *Neurobiol Aging* **34**:1504–1515.
- Jiang R and Carlson M (1996) Glucose regulates protein interactions within the yeast Snf1 protein kinase complex. *Genes Dev* **10**:3105–3115.
- Jiang R and Carlson M (1997) The Snf1 protein kinase and its activating subunit, Snf4, interact with distinct domains of the Sip1/Sip2/Gal83 component in the kinase complex. *Mol Cell Biol* **17**:2099–2106.
- Ju T-C, Chen H-M, Lin J-T, Chang C-P, Chang W-C, Kang J-J, Sun C-P, Tao M-H, Tu P-H, and Chang C et al. (2011) Nuclear translocation of AMPK- $\alpha$ 1 potentiates striatal neurodegeneration in Huntington's disease. *J Cell Biol* **194**:209–227.
- Kahn BB, Alquier T, Carling D, and Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. *Cell Metab* **1**:15–25.
- Kazgan N, Williams T, Forsberg LJ, and Brenman JE (2010) Identification of a nuclear export signal in the catalytic subunit of AMP-activated protein kinase. *Mol Biol Cell* **21**:3433–3442.
- Kemp BE, Oakhill JS, and Scott JW (2007) AMPK structure and regulation from three angles. *Structure* **15**:1161–1163.
- Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, and Sabatini DM (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. *Cell* **110**:163–175.
- Kim HS, Kim M-J, Kim EJ, Yang Y, Lee M-S, and Lim J-S (2012a) Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. *Biochem Pharmacol* **83**:385–394.
- Kim J, Kundu M, Viollet B, and Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol* **13**:132–141.
- Kim M, Hunter RW, Garcia-Mendez L, Gong G, Yang YY, Kolwicz SC, Jr, Xu J, Sakamoto K, Wang W, and Tian R (2014) Mutation in the  $\gamma$ 2-subunit of AMP-activated protein kinase stimulates cardiomyocyte proliferation and hypertrophy independent of glycogen storage. *Circ Res* **114**:966–975.
- Kim SY, Jeong S, Jung E, Baik K-H, Chang MH, Kim SA, Shim JH, Chun E, and Lee KY (2012b) AMP-activated protein kinase- $\alpha$ 1 as an activating kinase of TGF- $\beta$ -activated kinase 1 has a key role in inflammatory signals. *Cell Death Dis* **3**:e357.
- Koay A, Woodcroft B, Petrie EJ, Yue H, Emanuelle S, Bieri M, Bailey MF, Hargreaves M, Park JT, and Park KH et al. (2010) AMPK beta subunits display isoform specific affinities for carbohydrates. *FEBS Lett* **584**:3499–3503.
- Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, and Pan H et al. (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. *Nat Med* **10**:1344–1351.
- Kramer HF, Witzak CA, Fujii N, Jessen N, Taylor EB, Arnolds DE, Sakamoto K, Hirshman MF, and Goodyear LJ (2006) Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. *Diabetes* **55**:2067–2076.
- Krishnan S, Richardson DR, and Sahni S (2014) AMP kinase (PRKAA1). *J Clin Pathol* **67**:758–763.
- Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, and Winder WW (1999) 5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. *Diabetes* **48**:1667–1671.
- Landström M (2010) The TAK1-TRAF6 signalling pathway. *Int J Biochem Cell Biol* **42**:585–589.
- LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, and Tomas E (2006) Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. *Am J Physiol Endocrinol Metab* **291**:E175–E181.
- Lee M, Lee H-J, Seo WD, Park KH, and Lee Y-S (2010) Sialylation of integrin  $\beta$ 1 is involved in radiation-induced adhesion and migration in human colon cancer cells. *Int J Radiat Oncol Biol Phys* **76**:1528–1536.
- Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye J-M, Lee CH, Oh WK, and Kim CT et al. (2006) Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. *Diabetes* **55**:2256–2264.
- Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, and Cataldo NA et al.; Reproductive Medicine Network (2008) Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. *J Clin Endocrinol Metab* **93**:792–800.
- Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, and Shyy JY-J et al. (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. *Cell Metab* **13**:376–388.
- Light PE (2006) Familial Wolff-Parkinson-White Syndrome: a disease of glycogen storage or ion channel dysfunction? *J Cardiovasc Electrophysiol* **17** (Suppl 1): S158–S161.
- Lim MA, Selak MA, Xiang Z, Krainc D, Neve RL, Kraemer BC, Watts JL, and Kalb RG (2012) Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease. *J Neurosci* **32**:1123–1141.
- Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, and Thor AD (2011) Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. *Cell Cycle* **10**:2959–2966.
- Longnus SL, Wambolt RB, Parsons HL, Brownsey RW, and Allard MF (2003) 5-Aminoimidazole-4-carboxamide 1- $\beta$ -D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. *Am J Physiol Regul Integr Comp Physiol* **284**:R936–R944.
- Lopez-Lopez C, Dietrich MO, Metzger F, Loetscher H, and Torres-Aleman I (2007) Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease. *J Neurosci* **27**:824–831.
- Luptak I, Shen M, He H, Hirshman MF, Muzi N, Goodyear LJ, Yan J, Wakimoto H, Morita H, and Arad M et al. (2007) Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. *J Clin Invest* **117**:1432–1439.
- Marcus AJ and Zhou W (2010) LKB1 regulated pathways in lung cancer invasion and metastasis. *J Thorac Oncol* **5**:1883–1886.
- Martin-Castillo B, Dorca J, Vazquez-Martín A, Oliveras-Ferreras C, Lopez-Bonet E, Garcia M, Del Barco S, and Menendez JA (2010) Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. *Ann Oncol* **21**:187–189.
- McBride A, Ghilagaber S, Nikolaev A, and Hardie DG (2009) The glycogen-binding domain on the AMPK beta subunit allows the kinase to act as a glycogen sensor. *Cell Metab* **9**:23–34.
- Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley LC, and Manning BD (2014) Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. *Cell* **156**:771–785.
- Milakovic T and Johnson GV (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. *J Biol Chem* **280**:30773–30782.
- Miller RA, Chu Q, Xie J, Foretz M, Viollet B, and Birnbaum MJ (2013) Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. *Nature* **494**:256–260.
- Minokoshi Y, Alquier T, Furukawa N, Kim Y-B, Lee A, Xue B, Mu J, Foulfelle F, Ferré P, and Birnbaum MJ et al. (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. *Nature* **428**:569–574.
- Mitchellhill KI, Michell BJ, House CM, Stapleton D, Dyck J, Gamble J, Ullrich C, Witters LA, and Kemp BE (1997) Posttranslational modifications of the 5'-AMP-activated protein kinase beta1 subunit. *J Biol Chem* **272**:24475–24479.
- Momcilovic M, Hong SP, and Carlson M (2006) Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. *J Biol Chem* **281**:25336–25343.
- Momcilovic M, Iram SH, Liu Y, and Carlson M (2008) Roles of the glycogen-binding domain and Snf4 in glucose inhibition of SNF1 protein kinase. *J Biol Chem* **283**:19521–19529.
- Motoshima H, Goldstein BJ, Igata M, and Araki E (2006) AMPK and cell proliferation—AMPK as a therapeutic target for atherosclerosis and cancer. *J Physiol* **574**:63–71.
- Müller-Decker K and Fürstenberger G (2007) The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. *Mol Carcinog* **46**:705–710.
- Nakano A, Kato H, Watanabe T, Min K-D, Yamazaki S, Asano Y, Seguchi O, Higo S, Shintani Y, and Asanuma H et al. (2010) AMPK controls the speed of microtubule polymerization and directional cell migration through CLIP-170 phosphorylation. *Nat Cell Biol* **12**:583–590.
- Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, and Matsumoto K (1999) The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. *Nature* **398**:252–256.

- O'Neill HM (2013) AMPK and exercise: glucose uptake and insulin sensitivity. *Diabetes Metab J* **37**:1–21.
- Oakhill JS, Chen Z-P, Scott JW, Steel R, Castelli LA, Ling N, Macaulay SL, and Kemp BE (2010)  $\beta$ -Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). *Proc Natl Acad Sci USA* **107**:19237–19241.
- Oakhill JS, Scott JW, and Kemp BE (2012) AMPK functions as an adenylate charge-regulated protein kinase. *Trends Endocrinol Metab* **23**:125–132.
- Oakhill JS, Steel R, Chen ZP, Scott JW, Ling N, Tam S, and Kemp BE (2011) AMPK is a direct adenylate charge-regulated protein kinase. *Science* **332**:1433–1435.
- Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, and Nagai K et al. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs. *Nat Genet* **36**:40–45.
- Owen MR, Doran E, and Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex I of the mitochondrial respiratory chain. *Biochem J* **348**:607–614.
- Panov AV, Gutekunst C-A, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, and Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. *Nat Neurosci* **5**:731–736.
- Papanas N, Maltezos E, and Mikhailidis DP (2010) Metformin and cancer: licence to heal? *Expert Opin Investig Drugs* **19**:913–917.
- Park CE, Kim MJ, Lee JH, Min BI, Bae H, Choe W, Kim SS, and Ha J (2007) Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. *Exp Mol Med* **39**:222–229.
- Park J-J, Seo S-M, Kim E-J, Lee Y-J, Ko Y-G, Ha J, and Lee M (2012) Berberine inhibits human colon cancer cell migration via AMP-activated protein kinase-mediated downregulation of integrin  $\beta$ 1 signaling. *Biochem Biophys Res Commun* **426**:461–467.
- Pehmoller C, Treabak JT, Birk JB, Chen S, Mackintosh C, Hardie DG, Richter EA, and Wojtaszewski JF (2009) Genetic disruption of AMPK signaling abolishes both contraction- and insulin-stimulated TBC1D1 phosphorylation and 14-3-3 binding in mouse skeletal muscle. *Am J Physiol Endocrinol Metab* **297**:E665–E675.
- Polekhina G, Gupta A, van Denderen BJ, Feil SC, Kemp BE, Stapleton D, and Parker MW (2005) Structural basis for glycogen recognition by AMP-activated protein kinase. *Structure* **13**:1453–1462.
- Premananth M, Basavanagowdappa H, Mahesh M, and Suresh M (2014) Correlation of abdominal adiposity with components of metabolic syndrome, anthropometric parameters and insulin resistance, in obese and non obese, diabetics and non diabetics: a cross sectional observational study. (Mysore Visceral Adiposity in Diabetics Study). *Indian J Endocrinol Metab* **18**:676–682.
- Racanelli AC, Rothbart SB, Heyer CL, and Moran RG (2009) Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. *Cancer Res* **69**:5467–5474.
- Ramratnam M, Sharma RK, D'Auria S, Lee SJ, Wang D, Huang XYN, and Ahmad F (2014) Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. *J Am Heart Assoc* **3**:e00899.
- Rattan R, Giri S, Hartmann LC, and Shridhar V (2011) Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. *J Cell Mol Med* **15**:166–178.
- Roach WG, Chavez JA, Miinea CP, and Lienhard GE (2007) Substrate specificity and effect on GLUT4 translocation of the Rab GTPase-activating protein Tbc1d1. *Biochem J* **403**:353–358.
- Rozengurt E, Sinnett-Smith J, and Kisfalvi K (2010) Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. *Clin Cancer Res* **16**:2505–2511.
- Ruan Q, Lesort M, MacDonald ME, and Johnson GV (2004) Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. *Hum Mol Genet* **13**:669–681.
- Ruderman NB, Carling D, Prentki M, and Caciccedo JM (2013) AMPK, insulin resistance, and the metabolic syndrome. *J Clin Invest* **123**:2764–2772.
- Ruderman NB, Xu XJ, Nelson L, Caciccedo JM, Saha AK, Lan F, and Ido Y (2010) AMPK and SIRT1: a long-standing partnership? *Am J Physiol Endocrinol Metab* **298**:E751–E760.
- Russo GL, Russo M, and Ungaro P (2013) AMP-activated protein kinase: a target for old drugs against diabetes and cancer. *Biochem Pharmacol* **86**:339–350.
- Sahni S, Merlot AM, Krishan S, Jansson PJ, and Richardson DR (2014) Gene of the month: BECN1. *J Clin Pathol* **67**:656–660.
- Salt I, Celler JW, Hawley SA, Prescott A, Woods A, Carling D, and Hardie DG (1998) AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the  $\alpha$ 2 isoform. *Biochem J* **334**:177–187.
- Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, and Carling D (2007) Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. *Biochem J* **403**:139–148.
- Sano H, Kane S, Sano E, Miinea CP, Asara JM, Lane WS, Garner CW, and Lienhard GE (2003) Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. *J Biol Chem* **278**:14599–14602.
- Sapkota GP, Boudeau J, Deak M, Kieloch A, Morrice N, and Alessi DR (2002a) Identification and characterization of four novel phosphorylation sites (Ser31, Ser325, Thr336 and Thr366) on LKB1/STK11, the protein kinase mutated in Peutz-Jeghers cancer syndrome. *Biochem J* **362**:481–490.
- Sapkota GP, Deak M, Kieloch A, Morrice N, Goodarzi AA, Smythe C, Shiloh Y, Lees-Miller SP, and Alessi DR (2002b) Ionizing radiation induces ataxia telangiectasia mutated kinase (ATM)-mediated phosphorylation of LKB1/STK11 at Thr-366. *Biochem J* **368**:507–516.
- Sapkota GP, Kieloch A, Lizcano JM, Lain S, Arthur JS, Williams MR, Morrice N, Deak M, and Alessi DR (2001) Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell growth. *J Biol Chem* **276**:19469–19482.
- Sawin KE and Nurse P (1998) Regulation of cell polarity by microtubules in fission yeast. *J Cell Biol* **142**:457–471.
- Scholz R, Sidler CL, Thali RF, Winssinger N, Cheung PC, and Neumann D (2010) Autoactivation of transforming growth factor beta-activated kinase 1 is a sequential bimolecular process. *J Biol Chem* **285**:25753–25766.
- Shackelford DB and Shaw RJ (2009) The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. *Nat Rev Cancer* **9**:563–575.
- Shaw RJ (2009) LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. *Acta Physiol (Oxf)* **196**:65–80.
- Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, and Tanaka N et al. (2005) TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. *Genes Dev* **19**:2668–2681.
- Sidhu JS, Rajawat YS, Rami TG, Gollob MH, Wang Z, Yuan R, Marian AJ, DeMayo FJ, Weibacher D, and Taffet GE et al. (2005) Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. *Circulation* **111**:21–29.
- Song P, Xie Z, Wu Y, Xu J, Dong Y, and Zou MH (2008) Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. *J Biol Chem* **283**:12446–12455.
- Song XM, Fiedler M, Galuska D, Ryder JW, Fernström M, Chibalin AV, Wallberg-Henriksson H, and Zierath JR (2002) 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. *Diabetologia* **45**:56–65.
- Srivastava RAK, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, and Newton RS (2012) AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. *J Lipid Res* **53**:2490–2514.
- Steinberg GR and Kemp BE (2009) AMPK in health and disease. *Physiol Rev* **89**:1025–1078.
- Steinberg GR, O'Neill HM, Dzamko NL, Galic S, Naim T, Koopman R, Jørgensen SB, Honeyman J, Hewitt K, and Chen ZP et al. (2010) Whole body deletion of AMP-activated protein kinase  $\beta$ 2 reduces muscle AMPK activity and exercise capacity. *J Biol Chem* **285**:37198–37209.
- Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, and Altshul SF et al.; Mammalian Gene Collection Program Team (2002) Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. *Proc Natl Acad Sci USA* **99**:16899–16903.
- Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, and Beri RK (1994) Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. *FEBS Lett* **353**:33–36.
- Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, and Neumann D (2006) Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. *J Biol Chem* **281**:32207–32216.
- Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, and Sharma D (2009) LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. *Oncogene* **28**:2621–2633.
- Thampy KG (1989) Formation of malonyl coenzyme A in rat heart. Identification and purification of an isozyme of A carboxylase from rat heart. *J Biol Chem* **264**:17631–17634.
- Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. *Curr Opin Cell Biol* **15**:740–746.
- Thornton C, Bright NJ, Sastre M, Muckett PJ, and Carling D (2011) AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid  $\beta$ -peptide exposure. *Biochem J* **434**:503–512.
- Thornton C, Snowden MA, and Carling D (1998) Identification of a novel AMP-activated protein kinase beta subunit isoform that is highly expressed in skeletal muscle. *J Biol Chem* **273**:12443–12450.
- Tillhorn M, Guamán Ortiz LM, Lombardi P, and Scovassi AI (2012) Berberine: new perspectives for old remedies. *Biochem Pharmacol* **84**:1260–1267.
- Tosca L, Ramé C, Chabrolle C, Tesseraud S, and Dupont J (2010) Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells. *Reproduction* **139**:409–418.
- Turner N, Li J-Y, Gosby A, To SW, Cheng Z, Miyoshi H, Taketo MM, Cooney GJ, Kraegen EW, and James DE et al. (2008) Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. *Diabetes* **57**:1414–1418.
- Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, and Chung JH (2010) AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. *Diabetes* **59**:554–563.
- Vingtdéux V, Davies P, Dickson DW, and Marambaud P (2011) AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. *Acta Neuropathol* **121**:337–349.
- Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, and Andreelli F (2012) Cellular and molecular mechanisms of metformin: an overview. *Clin Sci (Lond)* **122**:253–270.
- Wakil SJ, Stoops JK, and Joshi VC (1983) Fatty acid synthesis and its regulation. *Annu Rev Biochem* **52**:537–579.
- Wakil SJ, Titchener EB, and Gibson DM (1958) Evidence for the participation of biotin in the enzymic synthesis of fatty acids. *Biochim Biophys Acta* **29**:225–226.
- Wang L, Di L, and Noguchi CT (2014) AMPK is involved in mediation of erythropoietin influence on metabolic activity and reactive oxygen species production in white adipocytes. *Int J Biochem Cell Biol* **54**:1–9.
- Warden SM, Richardson C, O'Donnell J, Jr, Stapleton D, Kemp BE, and Witters LA (2001) Post-translational modifications of the  $\beta$ -1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. *Biochem J* **354**:275–283.

- Winder WW (2001) Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. *J Appl Physiol* (1985) **91**:1017–1028.
- Woods A, Dickerson K, Heath R, Hong S-P, Momcilovic M, Johnstone SR, Carlson M, and Carling D (2005) Ca<sup>2+</sup>/calmodulin-dependent protein kinase kinase- $\beta$  acts upstream of AMP-activated protein kinase in mammalian cells. *Cell Metab* **2**:21–33.
- Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, and Carling D (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. *Curr Biol* **13**:2004–2008.
- Wullschlegel S, Loewith R, and Hall MN (2006) TOR signaling in growth and metabolism. *Cell* **124**:471–484.
- Xiao B, Heath R, Saiu P, Leiper FC, Leone P, Jing C, Walker PA, Haire L, Eccleston JF, and Davis CT et al. (2007) Structural basis for AMP binding to mammalian AMP-activated protein kinase. *Nature* **449**:496–500.
- Xiao B, Sanders MJ, Carmena D, Bright NJ, Haire LF, Underwood E, Patel BR, Heath RB, Walker PA, and Hallen S et al. (2013) Structural basis of AMPK regulation by small molecule activators. *Nat Commun* **4**:3017.
- Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, Carmena D, Jing C, Walker PA, Eccleston JF, and Haire LF et al. (2011) Structure of mammalian AMPK and its regulation by ADP. *Nature* **472**:230–233.
- Xie M, Zhang D, Dyck JR, Li Y, Zhang H, Morishima M, Mann DL, Taffet GE, Baldini A, and Khoury DS et al. (2006) A pivotal role for endogenous TGF- $\beta$ -activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. *Proc Natl Acad Sci USA* **103**:17378–17383.
- Xie Z, Dong Y, Zhang J, Scholz R, Neumann D, and Zou MH (2009) Identification of the serine 307 of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and endothelial cell angiogenesis. *Mol Cell Biol* **29**:3582–3596.
- Xin FJ, Wang J, Zhao RQ, Wang ZX, and Wu JW (2013) Coordinated regulation of AMPK activity by multiple elements in the  $\alpha$ -subunit. *Cell Res* **23**:1237–1240.
- Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, and Matsumoto K (1995) Identification of a member of the MAPKKK family as a potential mediator of TGF- $\beta$  signal transduction. *Science* **270**:2008–2011.
- Yin J, Xing H, and Ye J (2008) Efficacy of berberine in patients with type 2 diabetes mellitus. *Metabolism* **57**:712–717.
- Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, and Kim JB (2006) Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. *Diabetes* **55**:2562–2570.
- Yu X, McCorkle S, Wang M, Lee Y, Li J, Saha AK, Unger RH, and Ruderman NB (2004) Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. *Diabetologia* **47**:2012–2021.
- Zakikhani M, Dowling RJ, Sonenberg N, and Pollak MN (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. *Cancer Prev Res (Phila)* **1**:369–375.
- Zang M, Xu S, Maitland-Toolan KA, Zucollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, and Cohen RA (2006) Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. *Diabetes* **55**:2180–2191.
- Zhang BL, Xu RL, Zhang J, Zhao XX, Wu H, Ma LP, Hu JQ, Zhang JL, Ye Z, and Zheng X et al. (2013) Identification and functional analysis of a novel PRKAG2 mutation responsible for Chinese PRKAG2 cardiac syndrome reveal an important role of non-CBS domains in regulating the AMPK pathway. *J Cardiol* **62**:241–248.
- Zhang BL, Ye Z, Xu RL, You XH, Qin YW, Wu H, Cao J, Zhang JL, Zheng X, and Zhao XX (2014b) Overexpression of G100S mutation in PRKAG2 causes Wolf-Parkinson-White syndrome in zebrafish. *Clin Genet* **86**:287–291.
- Zhang CS, Jiang B, Li M, Zhu M, Peng Y, Zhang YL, Wu YQ, Li TY, Liang Y, and Lu Z et al. (2014a) The lysosomal v-ATPase-Ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. *Cell Metab* **20**:526–540.
- Zheng B and Cantley LC (2007) Regulation of epithelial tight junction assembly and disassembly by AMP-activated protein kinase. *Proc Natl Acad Sci USA* **104**:819–822.
- Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, and Fujii N et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest* **108**:1167–1174.
- Zhu L, Chen L, Zhou XM, Zhang YY, Zhang YJ, Zhao J, Ji SR, Wu JW, and Wu Y (2011) Structural insights into the architecture and allostery of full-length AMP-activated protein kinase. *Structure* **19**:515–522.

**Address correspondence to:** Dr. Des R. Richardson, Molecular Pharmacology and Pathology Program, Department of Pathology, Blackburn Building D06, University of Sydney, Sydney, New South Wales, 2006, Australia. E-mail: d.richardson@sydney.edu.au or Dr. Sumit Sahni, Molecular Pharmacology and Pathology Program, Department of Pathology, Blackburn Building D06, University of Sydney, Sydney, New South Wales, 2006, Australia. E-mail: sumit.sahni@sydney.edu.au